Loading page
Loading page
Loading substance route
Effects demonstrate a steep dose-response curve; increments as small as 2 mg within the 12–24 mg range may produce profound shifts in subjective intensity and character. Gradual titration in initial trials is strongly advised.
Effects vary widely by individual, dose, and context.
The physical effects of 2C-B can be broken down into five components all of which progressively intensify proportional to dosage.
The head space of 2C-B is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
2C-B presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of LSD than that of 2C-E, psilocin, or ayahuasca. They can be comprehensively described as unstructured in their organization, algorithmic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, sharp in their edges and angular in their corners. They seem high in algorithmic visuals such as fractals and at higher dosages are significantly more likely to result in states of Level 7A visual geometry over Level 7B.
Like LSD, while 2C-B is capable of producing a full range of low and high level hallucinatory states, this is extremely rare and inconsistent at higher levels but common at lower levels.
The auditory effects of 2C-B are more common than some psychedelics in their occurrence and are capable of producing a full range of effects.
2C-B functions primarily as a partial agonist at the serotonin 5-HT2 receptor family, with potent binding at 5-HT2A, 5-HT2C, and to a lesser degree 5-HT2B. Some studies have reported low efficacy or antagonism at 5-HT2A and 5-HT2C, while others have consistently measured near-full efficacy at these sites. Beyond the 5-HT2 receptors, 2C-B shows modest affinity for 5-HT1A and 5-HT1B receptors and has been characterized as a non-competitive serotonin transporter inhibitor of very low potency. Research in rat models has also demonstrated that 2C-B increases dopamine levels, which may contribute to its psychoactive profile.
2C-B appears to have relatively low oral bioavailability as a result of substantial first-pass metabolism in the liver. It is metabolized by hepatocytes through oxidative deamination and demethylation, with deamination catalyzed by both MAO-A and MAO-B. Species differences exist in the metabolic products; human, monkey, and rabbit hepatocytes produce the demethylated metabolite B-2-HMPE, while dog, rat, and mouse hepatocytes do not. The primary metabolite BDMPAA reaches plasma concentrations approximately 280-fold higher than 2C-B itself after oral dosing. The elimination half-life in humans ranges from 1.2 to 2.5 hours.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-B is considered non-addictive with a low potential for abuse. Like other serotonergic psychedelics, it possesses a self-regulating quality that discourages compulsive use patterns.
2C-B does not produce physical dependence. Withdrawal effects following discontinuation have not been reported.
The fatal dose of 2C-B in humans is unknown, but no deaths have been attributed to 2C-B alone as of 2018. Alexander Shulgin reported a 100mg accidental oral dose was survived without apparent harm. The safety window is thought to be narrower than LSD and psilocybin but similar to mescaline. Three case reports of 2C-B intoxication exist in the scientific literature as of 2015.
Acute cardiovascular effects including elevated blood pressure, increased heart rate, and hyperthermia occur during intoxication, particularly at higher doses; theoretical risk of cardiac valvulopathy exists with frequent long-term use due to 5-HT2B agonism, though this has not been documented in 2C-B users specifically.
At typical recreational doses, 2C-B is unlikely to be neurotoxic; severe neurological impairment has been reported in isolated case reports involving unknown doses or possible adulterants.
Adverse psychological reactions including anxiety, paranoia, delusions, and psychosis are possible, particularly in those predisposed to mental disorders. One case report documents persistent psychosis following a single dose. Individuals with a family history of schizophrenia or early onset mental illness should exercise extreme caution.
Seizures are rare but have been documented in at least one case report involving an unknown dose that also produced serotonin syndrome. Risk may increase in susceptible individuals or when combined with seizure threshold-lowering substances.
2C-B was first synthesized in 1974 by American chemist Alexander Shulgin while investigating novel psychedelic compounds based on the chemical structure of mescaline, specifically exploring homologues of DOB. Its psychoactive properties were discovered on June 25, 1975, when Shulgin tested the…
UN Convention on Psychotropic Substances Schedule II (added March 2001)
Classified as a Schedule I controlled substance alongside similar phenethylamines such as 2C-I and 2C-T-2.
Prohibited under the Suchtmittelgesetz (SMG). Specifically listed in Schedule V of the Suchtgiftverordnung, making possession, production, and sale illegal.
Listed on Portaria SVS/MS nº 344, making production, distribution, and possession illegal.
Added to Ley 20.000 (known as Ley de drogas) in August 2007 along with many other psychoactive substances.
Possession of more than 200 mg is punishable by up to two years imprisonment. Smaller amounts may result in a fine. The 200 mg threshold serves as a guideline which courts may adjust based on circumstances.
Classified as a Schedule I controlled substance, prohibiting possession, production, and distribution.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since January 31, 1993, listed as 'Bromdimethoxyphenethylamin' (BDMPEA). Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
Controlled since Summer 1998. Prior to scheduling, it was marketed as a sexual enhancement product under the name 'Performax.'
Classified as a prohibited substance since 2001.
Classified as Schedule II since March 22, 2004, listed under the name 4-bromo-2,5-dimethoxyphenethylamine.
Banned as a narcotic drug since October 2011. Possession of 10 mg or more carries criminal penalties.
Added to Category 2 prohibited substances in 2002.
Listed in Anhang D (Verzeichnis D) of the Verordnung des EDI über die Verzeichnisse der Betäubungsmittel (DetMV). Possession is illegal.
Controlled as a Class A substance under the Misuse of Drugs Act due to the phenethylamine catch-all clause, applying to all drugs in the 2C family. Production, supply, and possession are illegal. Possession carries a maximum sentence of seven years imprisonment; supply is punishable by life imprisonment and an unlimited fine.
Considered a prohibited substance under the Poisons Standard. First placed on Schedule One of the Drugs Misuse and Trafficking Act in 1994 and included on the list of substances subject to import and export controls. Also falls under the Australian analogue act provisions.
Added to the list of illegal psychotropic substances on April 30, 2002. Production, distribution, and possession are prohibited.
Classified under the Controlled Drugs and Substances Act as '4-bromo-2,5-dimethoxybenzeneethanamine and any salt, isomer or salt of isomer thereof.' Originally scheduled in April 1997, then rescheduled in an amendment effective October 31, 2016 to include other 2C-x analogues.
Prohibited as a result of being classified as a 2,5-dimethoxyphenylethanamine derivative.
Classified as a Category B controlled substance under Danish drug legislation.
Listed in the government decree on substances, preparations, and plants considered to be narcotic drugs, classified in the hard-drug category.
Listed in Tabella I of 'Tabelle delle sostanze stupefacenti e psicotrope,' making possession, purchase, and sale illegal.
Classified as a Schedule I controlled substance, prohibiting possession, production, and distribution.
Scheduled as a hard drug under the Opium Law on July 9, 1997. The Netherlands became the first country to ban 2C-B and related phenethylamines (2C-I, 2C-T-2, 2C-T-7) following the emergence of these substances as alternatives.
Listed in the I-P group under 'Wykaz środków odurzających i substancji psychotropowych.' Possession has been illegal since 2015.
Classified as a controlled substance under national drug legislation.
Currently classified as Schedule I. First regulated on April 1, 1999 as a 'health hazard' under the Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:58), then promoted to Schedule I effective June 1, 2002.
Classified as a controlled drug. Possession, production, supply, and import are prohibited.
Classified as a Schedule I controlled substance. Initially scheduled on January 6, 1994, with permanent scheduling effective June 2, 1995 following a DEA proposal in December 1994. Manufacturing, purchasing, possession, and distribution without a DEA license are prohibited.
22 sources cited
